Published in Int J Cancer on January 01, 2003
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature (2015) 1.87
A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother (2009) 1.75
MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol (2008) 1.38
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med (2012) 1.23
Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells. Biochem J (2003) 1.15
Anti-MUC1 antibodies and ovarian cancer risk: prospective data from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev (2010) 1.15
Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes Control (2010) 1.03
Shifting the paradigm in radiation safety. Dose Response (2012) 1.02
Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer. Proc Natl Acad Sci U S A (2009) 0.97
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97
Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol (2010) 0.96
MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis. BMC Cancer (2006) 0.93
Natural and Induced Humoral Responses to MUC1. Cancers (Basel) (2011) 0.93
Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer (2008) 0.92
Biological approaches to therapy of pancreatic cancer. Pancreatology (2008) 0.91
Pancreatic ductal adenocarcinoma: a review of immunologic aspects. J Investig Med (2012) 0.91
Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. Int J Cancer (2014) 0.89
Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. Biomark Insights (2006) 0.89
The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray. Electrophoresis (2009) 0.89
MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol (2005) 0.88
A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection. Oncotarget (2016) 0.87
Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells. Oncoimmunology (2014) 0.87
Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol Immunol (2009) 0.86
Mucins differently expressed in various ampullary adenocarcinomas. Diagn Pathol (2011) 0.86
Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study. Cancer (2012) 0.85
Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother (2014) 0.84
Autoantibodies to tumor-associated antigens in epithelial ovarian carcinoma. J Oncol (2010) 0.84
What is recent in pancreatic cancer immunotherapy? Biomed Res Int (2012) 0.84
Linking the ovarian cancer transcriptome and immunome. BMC Syst Biol (2008) 0.81
Detection of circulating anti-mucin 1 (MUC1) antibodies in breast tumor patients by indirect enzyme-linked immunosorbent assay using a recombinant MUC1 protein containing six tandem repeats and expressed in Escherichia coli. Clin Vaccine Immunol (2010) 0.80
The relation of the level of serum anti-TF, -Tn and -alpha-Gal IgG to survival in gastrointestinal cancer patients. Int J Med Sci (2013) 0.79
The identification of auto-antibodies in pancreatic cancer patient sera using a naturally fractionated Panc-1 cell line. Cancer Biomark (2010) 0.78
An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells. Br J Cancer (2003) 0.78
Higher levels of antibodies to the tumour-associated antigen cyclin B1 in cancer-free individuals than in patients with breast cancer. Clin Exp Immunol (2014) 0.77
Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas (2016) 0.77
Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses. Bioconjug Chem (2015) 0.76
Naturally occurring antibodies to epithelial cell adhesion molecule (EpCAM). Dig Dis Sci (2003) 0.76
Local effects of regulatory T cells in MUC1 transgenic mice potentiate growth of MUC1 expressing tumor cells in vivo. PLoS One (2012) 0.76
New tumor-associated antigen SC6 in pancreatic cancer. World J Gastroenterol (2005) 0.75
Valency and density matter: Deciphering impacts of immunogen structures on immune responses against a tumor associated carbohydrate antigen using synthetic glycopolymers. Biomaterials (2016) 0.75
One Step Assembly of Thin Films of Carbon Nanotubes on Screen Printed Interface for Electrochemical Aptasensing of Breast Cancer Biomarker. Sensors (Basel) (2016) 0.75
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature (2003) 4.80
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res (2008) 3.81
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res (2012) 2.45
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. Am J Gastroenterol (2012) 2.06
Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene (2003) 1.91
A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. Mod Rheumatol (2006) 1.91
DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology (2008) 1.83
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene (2005) 1.82
Clinical and pathological characteristics of Mikulicz's disease (IgG4-related plasmacytic exocrinopathy). Autoimmun Rev (2004) 1.80
Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci U S A (2006) 1.74
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet (2004) 1.66
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood (2003) 1.65
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Risk of malignancies in IgG4-related disease. Mod Rheumatol (2011) 1.61
Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol (2004) 1.59
Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J (2002) 1.59
Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res (2005) 1.58
Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci U S A (2003) 1.57
Intractable colitis associated with chronic granulomatous disease. J Med Microbiol (2006) 1.56
New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol (2002) 1.54
The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol (2003) 1.53
Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis (2007) 1.52
Methylation-associated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis (2010) 1.52
The p53 family member genes are involved in the Notch signal pathway. J Biol Chem (2001) 1.50
MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res (2006) 1.46
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology (2004) 1.43
Usefulness of narrow-band imaging endoscopy for diagnosis of Barrett's esophagus. J Gastroenterol (2004) 1.40
Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res (2011) 1.40
Tophaceous gout in the cervical spine. Intern Med (2012) 1.40
Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc (2002) 1.40
Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer (2006) 1.37
Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One (2012) 1.35
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis (2009) 1.34
Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol (2011) 1.33
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol (2012) 1.31
The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology (2005) 1.30
Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia (2008) 1.28
Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol (2007) 1.27
MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLoS One (2013) 1.27
Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res (2003) 1.27
Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res (2005) 1.26
Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. J Gastroenterol (2008) 1.25
MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res (2007) 1.25
Association of the -173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol (2004) 1.25
Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma. Int J Cancer (2011) 1.24
Simple genotype analysis of the Asp299Gly polymorphism of the Toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal (2002) 1.23
Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene (2002) 1.23
MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer (2006) 1.22
PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res (2007) 1.21
Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res (2006) 1.21
Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Res (2007) 1.20
Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosomes Cancer (2002) 1.20
Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res (2007) 1.18
Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Am J Pathol (2012) 1.17
Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res (2003) 1.16
MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 (MAP2K1) in human bladder cancer. Carcinogenesis (2011) 1.16
Identification of SCN3B as a novel p53-inducible proapoptotic gene. Oncogene (2004) 1.16
Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci (2007) 1.14
A novel correlation between LINE-1 hypomethylation and the malignancy of gastrointestinal stromal tumors. Clin Cancer Res (2010) 1.14
Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res (2009) 1.14
Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis. Clin Cancer Res (2004) 1.13
Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer (2002) 1.12
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. Gastroenterology (2005) 1.12
The birthday of a new syndrome: IgG4-related diseases constitute a clinical entity. Autoimmun Rev (2010) 1.12
Ku70 and poly(ADP-ribose) polymerase-1 competitively regulate beta-catenin and T-cell factor-4-mediated gene transactivation: possible linkage of DNA damage recognition and Wnt signaling. Cancer Res (2007) 1.11
Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer (2006) 1.11
Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. J Pathol (2003) 1.11
CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res (2007) 1.11
Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res (2004) 1.11
TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer (2010) 1.10
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis. Eur J Cancer (2006) 1.09
Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol (2003) 1.09
A requirement for DICER to maintain full promoter CpG island hypermethylation in human cancer cells. Cancer Res (2008) 1.08
CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood (2008) 1.08
Gastrointestinal cancer of the microsatellite mutator phenotype pathway. J Gastroenterol (2002) 1.08
LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol Biomarkers Prev (2008) 1.08
Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer. Tumour Biol (2004) 1.08
Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis (2006) 1.07
Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther (2011) 1.07
Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol (2003) 1.06